Aeterna Zentaris (NASDAQ:AEZS) Stock Passes Above 200-Day Moving Average – What’s Next?

Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ)’s share price crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $3.10 and traded as high as $3.19. Aeterna Zentaris shares last traded at $2.84, with a volume of 1,649 shares traded.

Analysts Set New Price Targets

Separately, StockNews.com assumed coverage on shares of Aeterna Zentaris in a report on Thursday. They issued a “sell” rating on the stock.

Aeterna Zentaris Price Performance

The stock has a market cap of $5.09 million, a price-to-earnings ratio of -0.19 and a beta of 1.55. The stock’s 50-day moving average is $2.89 and its 200-day moving average is $3.10.

About Aeterna Zentaris

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis.